[High-dosage chemo-radiotherapy with autologous bone marrow transfusion in malignant lymphoma: indications and personal experience].
We report the results of a pilot study of dose intensification with autologous bone marrow support in patients with malignant lymphoma. Since January 1988 11 patients with malignant lymphoma have been treated by intensive chemoradiotherapy or combination chemotherapy followed by autologous bone marrow support. 6 of the patients had non-Hodgkin's lymphoma in first remission with unfavorable histology and/or unfavorable clinical prognostic factors, and 5 patients were in second or subsequent remission (2 non-Hodgkin's lymphoma, 3 Hodgkin's disease). Bone marrow harvest and cryopreservation of marrow cells were uneventful. 10 patients showed full hematologic recovery, while one patient with Hodgkin's disease died early of pneumocystis pneumonia. With the exception of one interstitial pneumonitis of unknown etiology, the clinical course during hospitalization was otherwise uncomplicated. The mean duration of hospital stay was 33 days. 2 patients relapsed after dose intensification, while the others are in continued remission (median 7 months, range 2-14 months).
Stahel
R A
RA
Abteilung für Onkologie, Universitätsspital Zürich.
Jost
L M
LM
Burger
J
J
Honegger
H P
HP
Brun del Re
G P
GP
Gmür
J
J
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D005260:Female; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D011879:Radiotherapy Dosage; D012074:Remission Induction; D014182:Transplantation, Autologous; D014916:Whole-Body Irradiation
Hochdosierte Chemoradiotherapie mit Retransfusion autologen Knochenmarks bei malignen Lymphomen: Indikationen und eigene Erfahrungen.